Therapeutic results obtained in vaginal mycoses after single-dose treatment with 500 mg clotrimazole vaginal tablets

Fleury, Frederick J.; Hughes, Dominic; Floyd, Rebecca

doi:10.1016/s0002-9378(85)80013-2

Cited by 11 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In relation to the safety, the present results showed minimal side-effect without adverse event. In clinical practice, Fluconazole has advantage due to oral form, and can be used more easily, compared to Sertaconazole (500 mg) and Clotrimazole (100 mg) in vaginal form [21]. Antifungal vaginal tablet is still favorably used because of the belief that vaginal disease should be treated by vaginal medication.…”

Section: Discussionmentioning

confidence: 99%

“…Antifungal vaginal tablet is still favorably used because of the belief that vaginal disease should be treated by vaginal medication. Some Thai females trust the six-day regimen [21] of vaginal tablets more than one-day regimen, although several studies show equal antifungal efficacy between the two regimens. The one-day regimen (500 mg Sertaconazole vaginal tablet) [22] seemed to be less popular than the previous six-day regimen (100 mg Clotrimazole vaginal tablet).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of a new imidazole fungicide, Sertaconazole, in the treatment of fungal vulvo-vaginitis: a comparative study using Fluconazole and Clotrimazole

Roongpisuthipong¹,

Chalermchockcharoenkit²,

Sirimai³

et al. 2010

Asian Biomedicine

View full text Add to dashboard Cite

Background: Sertaconazole is a new imidazole fungicide introduced for vulvo-vaginal candidiasis. It has an azole group with benzothiophene that inhibits biosynthesis of ergosterol and brings about a massive leak of cytoplasm with consequent fungal cell death. Objective: Assess the safety and efficacy of Sertaconazole in the treatment of fungal vulvo-vaginitis for comparison with Fluconazole and Clotrimazole. Subjects and methods: One-hundred eighty-eight outpatients with fungal vulvo-vaginitis were recruited at Siriraj Hospital, Thailand between August 31, 2004 and January 30, 2006. The patients were given Sertaconazole, Fluconazole, or Clotrimazole, and received vaginal swab and culture for fungus at seventh and 28th days after treatment. Results: Out of 188 cases, 177 cases were followed-up completely. Sertaconazole group included 66 cases where 35 cure, 20 fail, and 7 recurrent cases. Fluconazole group included 60 cases and had 37 cure, six fail, and 20 recurrence cases. Clotrimazole group included 55 cases and had 32 cure, nine fail and 11 recurrent cases. There were risk factors of fungal vulvo-vaginitis, including frequent micturition and small toilet shower flushing. Conclusion: Sertaconazole had similar effectiveness and less side-effect as compared with Fluconazole and Clotrimazole. It appeared to work well with lowest recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%